Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 29-38 , July 2008

Relief of Incident Dyspnea in Palliative Cancer Patients: A Pilot, Randomized, Controlled Trial Comparing Nebulized Hydromorphone, Systemic Hydromorphone, and Nebulized Saline

  • Margaret A. Charles, PhD

      Affiliations

    • School of Psychology, Sydney University, Sydney, New South Wales
    • Corresponding Author InformationAddress correspondence to: Margaret A. Charles, PhD, School of Psychology A18, University of Sydney, NSW 2006, Australia.
    • ,
  • Liz Reymond, MBBS(Hons), PhD, FAChPM

      Affiliations

    • Brisbane South Palliative Care Collaborative, Mt. Olivet Hospital, Brisbane, Queensland, Australia
    • ,
  • Fiona Israel, MCouns

      Affiliations

    • Brisbane South Palliative Care Collaborative, Mt. Olivet Hospital, Brisbane, Queensland, Australia

,Accepted 31 August 2007.

References 

  1. Chandler S. Nebulized opioids to treat dyspnea. Am J Hosp Palliat Care. 1999;16:418–422
  2. O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care. 1999;8:37–43
  3. Jennings AL, Davies AN, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness (Cochrane Review). In: The Cochrane Library. Issue 3:Oxford: Update Software; 2003;
  4. Abernethy AP, Currow D, Frith P, et al. Randomised, double blind placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327:523–528
  5. Rogers DF, Barnes PJ. Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1989;1(8644):930–932
  6. Zebraski SE, Kochenash SM, Minireview Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66(23):2221–2231
  7. Chrubasik J, Wust H, Friedrich G, Geller E. Absorption and bioavailability of nebulised morphine. Br J Anaesth. 1988;61:228–230
  8. Masood A, Macmillan K, Pither J. Systemic absorption of nebulised morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996;41:250–252
  9. Quelch PC, Faulkner DE, Yun JWS. Nebulized opioids in the treatment of dyspnea. J Palliat Care. 1997;13(3):48–52
  10. Sarhill N, Walsh D, Khawam E, Tropiano P, Stahley MK. Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000;17(6):389–391
  11. Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med. 1997;11:267–275
  12. Farncombe M, Chater S, Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994;8:306–312
  13. Tanaka K, Shima Y, Kakinuma R, et al. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clinical Oncol. 1999;29(12):600–603
  14. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989;44:387–390
  15. Masood AR, Reed JW, Thomas SHL. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995;50:629–634
  16. Davis C, Hodder C, Love S. Effect of nebulised morphine and morphine 6-glucuronidide on exercise endurance in patients with chronic obstructive airway disease (Abstract). Thorax. 1994;49:393
  17. Breura E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29(6):613–618
  18. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996;51:596–600
  19. Enck RE. The role of nebulized morphine in managing dyspnea. Amer J Hosp Palliat Care. 1999;16:373–374
  20. Houde RW, Wallenstein Sl, Beaver WT, et al. Studies in methodology: hydromorphone vs morphine. In: Analgesic studies at the Sloan-Kettering Institute for Cancer Research reported to the 31st Annual Meeting of the Committee on Problems of Drug Dependence. Washington, DC: National Research Council, National Academy of Sciences, 1969:5916–5918.
  21. Houde RW. Clinical analgesic studies of hydromorphone. In:  Foley KM,  Inturrisi CE editor. Advances in pain research and therapy. vol. 8:New York, NY: Raven Press; 1986;p. 129–135
  22. Jennings AL, Daviea AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939-934
  23. Altman DG. Practical statistics for medical research. 1991. BocaRaton, Florida: Chapman & Hall/CRC; 1991;
  24. Hojat M, Xu G. A visitor's guide to effect sizes—statistical significance versus practical (clinical) importance of research findings. Adv Health Sci Educ. 2004;241–249
  25. Lasheen W, Panneerselvan A, Davis MP. Can we really say that nebulized morphine works?. J Pain Symptom Manage. 2006;32(2):101–102
  26. Bruera E. Author's response: can we really say that nebulised morphine works?. J Pain Symptom Manage. 2006;32(2):102–103
  27. Davis CL, Penn K, A'Hern R, Daniels J, Stevin M. Single dose randomised controlled trial of nebulized morphine in patients with cancer related breathlessness (Abstract). Palliat Med. 1996;10:64–65
  28. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev. 2006;58:1076–1088
  29. Pedersen S. Inhalers and nebulizers: which to use and why. Respir Med. 1996;90:69–77
  30. Wood JA, Wilson RSE, Bray C. Changes in salbutamol concentration in the reservoir solution of a jet nebuliser. Br J Dis Chest. 1986;80:164–169
  31. Clay MM, Pavia D, Newman S, Lennard-Jones TR, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet. 1983;2(8350):592–594
  32. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulised morphine. Eur Respir J. 1997;10:1079–1083

 This study was funded by the Sisters of Charity, Mt. Olivet Community Hospice Services, Brisbane, Queensland, Australia. The authors have no conflicts of interest to declare.

PII: S0885-3924(08)00066-3

doi: 10.1016/j.jpainsymman.2007.08.016

Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 29-38 , July 2008

Article Tools

* Image Usage & Resolution